Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization

A method of lessening, reducing, mitigating, ameliorating, or delaying pancreatic cancer in a subject, the method comprising administering a polysaccharide preparation having anti-Xa activity of less than 20 IU/mg and anti-IIa activity of 1 IU/mg or less;

• greater than 5% and less than 25% glycol split uronic acid residues;
• a plurality of polysaccharide chains of the preparation having a glycol split uronic acid residue (UG), wherein, the plurality of polysaccharide chains of the preparation each have no more than 3 glycol split uronic acid residues (UG);
• and the polysaccharide preparation has a molecular weight distribution such that 10-40% of the oligosaccharides of the preparation have a molecular weight <3000 Da;
• 45-65% of the oligosaccharides have a molecular weight between 3000-8000 Da, and 15-30% of the oligosaccharides have a molecular weight >8000 Da, wherein, the preparation comprises polysaccharides of Formula I:
• [Uw-Hx,y,z]m˜[UG-Hx,y,z]n
• wherein each occurrence of U indicates a uronic acid residue and each occurrence of H indicates a hexosamine residue;
• wherein m and n are integers such that
• m=4-16, and
• n=1-4:
• each of w, x, y and z can independently be the same or different for each occurrence of [Uw-Hx,y,z] and each of x, y and z can independently be the same or different for each occurrence of [UG-Hx,y,z], wherein
• w=-2OS or -2OH;
• x=—NS or —NAc;
• y=-3OS or -3OH;
• z=-6OS or -6OH;
• and
• wherein the symbol ˜ indicates that the units marked m and n are distributed along the polysaccharide chain and are not necessarily in sequence.

A method of lessening, reducing, mitigating, ameliorating, or delaying pancreatic cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising a polysaccharide preparation having the following characteristics:

• (a) a weight average chain molecular weight between 3,500 and 8,000 Da;
• (b) a molecular weight distribution such that 10-40% of the polysaccharides of the preparation have a molecular weight <3000 Da;
• 45-65% of the polysaccharides have a molecular weight between 3000-8000 Da, and 15-30% of the polysaccharides have a molecular weight >8000 Da;
• (c) greater than 5% and less than 25% glycol split uronic acid residues;
• (d) anti-Xa activity of less than 15 IU/mg and anti-IIa activity of 1 IU/mg or less, wherein, the preparation comprises polysaccharides of Formula I:
• [Uw-Hx,y,z]m˜[UG-Hx,y,z]n
• wherein each occurrence of U indicates a uronic acid residue and each occurrence of H indicates a hexosamine residue;
• wherein m and n are integers such that
• m=4-16, and
• n=1-3;
• each of w, x, y and z can independently be the same or different for each occurrence of [Uw-Hx,y,z] and each of x, y and z can independently be the same or different for each occurrence of [UG-Hx,y,z], wherein
• w=-2OS or -2OH;
• x=—NS or —NAc;
• y=-3OS or -3OH;
• z=-6PS or -6OH;
• and
• wherein the symbol ˜ indicates that the units marked m and n are distributed along the polysaccharide chain and are not necessarily in sequence;
• and
• wherein a plurality of the polysaccharides on the preparation have a 2,5-anhydromannitol residue at the reducing end and non native uronic acid at the non-reducing end.